At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Sep 10, 2026 at 06:00 ET
Axogen acquires BioCircuit Technologies for $200M cash, adding NerveTape, the first FDA-approved sutureless peripheral nerve repair device. The deal is expected to close in Q4 2026, funded by a concurrent public offering of Axogen common stock. Management expects the acquisition to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year post-close while maintaining positive free cash flow.
- Acquisition of BioCircuit Technologies for $200M in cash at closing.
- NerveTape is the first FDA-approved device for sutureless peripheral nerve repair.
- Transaction expected to close in Q4 2026, subject to customary conditions and spin-out of BioCircuit's electronics R&D business.
- Purchase price funded by net proceeds from a concurrent public offering of Axogen common stock.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access